Buscar
IDEAYA Biosciences Inc
IDYAAñadir a la lista de seguimiento
38.340USD
-0.270-0.70%
Horarios del mercado 09/18, 13:26（ET）
3.70BCap. mercado
PérdidaP/E TTM
Más Datos de IDEAYA Biosciences Inc Compañía
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Perfil de IDEAYA Biosciences Inc
Símbolo de cotizaciónIDYA
Nombre de la empresaIDEAYA Biosciences Inc
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 23
Dirección7000 Shoreline Ct, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504436209
Sitio Webhttps://www.ideayabio.com/
Símbolo de cotizaciónIDYA
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Ejecutivos de IDEAYA Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott William Morrison, CPA
Mr. Scott William Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de IDEAYA Biosciences Inc?
Los cinco principales accionistas de IDEAYA Biosciences Inc son: Mr. Douglas B. (Doug) Snyder
¿Cuántas instituciones poseen acciones de IDEAYA Biosciences Inc (IDYA)?
A fecha de 2026Q1, 518 instituciones poseen acciones de IDEAYA Biosciences Inc, con un valor de mercado combinado de aproximadamente 97.55M, lo que representa el 111.03% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -12932948.00.